This AI Tool For Diagnosing Autism Could Hit The Market ‘In The Second Half Of 2021’

Graison Dangor Contributor Healthcare I cover the intersection of mental health, the economy, and policy. A tool that helps pediatricians diagnose autism with artificial intelligence and smartphone video passed a key FDA test and could hit the market as soon as next summer, according to device-maker Cognoa, which recently announced its plans to submit the tool for final approval. In…

Cognoa moves ahead on FDA clearance of digital autism diagnostic

By Meg Bryant Children with autism spectrum disorder (ASD) can face a lifetime of frustration because of challenges with communication, social behaviors and flexibility of thought. Early intervention can improve outcomes, but nailing a diagnosis of ASD often takes years. Cognoa Inc. wants to change that with its digital ASD Diagnostic and is on track to apply for U.S. FDA clearance before the…

Cognoa’s AI-powered diagnostic app for autism clears clinical study, heads for FDA review

by Conor Hale Cognoa aims to equip primary care pediatricians with an artificial-intelligence-powered digital app that can spot the signs of autism, allowing them to rule out or diagnose spectrum disorders within the doctor’s office or remotely. This could represent a broad shift in the standard of care, as most children are referred to specialists for diagnosis and later treatment—a process…

AI Tool to Diagnose Autism Could Give Concerned Parents a Fast Diagnosis

The startup Cognoa has submitted its app-based tool for FDA clearance By Megan Scudellari This week, a California-based company announced it will seek FDA clearance for a first-of-its-kind autism spectrum disorder (ASD) diagnostic tool. Cognoa’s technology uses artificial intelligence to make an ASD diagnosis within weeks of signs of concern—far faster than the current standard of care. If cleared by the FDA, it would be…

Cognoa logo.

Cognoa Seeks FDA Clearance for Breakthrough Digital Autism Diagnostic Device After Successful Pivotal Study

Cognoa’s autism diagnostic device is positioned to be the first FDA-cleared digital solution enabling pediatricians to diagnose autism – a paradigm shift in the standard of care (Palo Alto, Calif. – September 23, 2020) – Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, announced today that…

How AI can overcome gender bias in autism diagnosis and treatment

Researchers and advocates have convincingly shown that the wide gap in diagnoses between boys and girls isn’t simply a matter of boys being significantly more likely to be on the autism spectrum. By DAVID HAPPEL Statistically, boys are four times as likely as girls to receive a diagnosis of autism spectrum disorder (ASD). But that’s not because boys are four times as likely to have ASD. According…

Cognoa Appoints Industry Leader David Happel as New Chief Executive Officer

Happel takes up the top job at Cognoa after over 25 years of successfully commercializing medical products and as a leader in the biotech and biopharma industries.  (Palo Alto, Calif. – March 24, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today the appointment of David Happel as Chief Executive Officer. Cognoa’s former CEO…

Can AI Help With Autism Diagnosis?

An Interview with Cognoa’s CEO Brent Vaughan In the US, one in five children are living with a diagnosable behavioral health disorder; however, only 21% of those children who are diagnosed receive needed treatment. Often, parents have to wait one to three years to receive a proper and accurate diagnosis, and an individualized treatment plan for their child. For the last 15 years, the average…

Location

Social